GAMUNEX-C

Phase 3Biologic

Grifols Therapeutics LLC

GAMUNEX-C is one of 102 biologic programs targeting Corneal Neovascularization. It is currently in Phase 3.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

Corneal NeovascularizationActive, not recruiting

MyopathyActive, not recruiting

ImmunodeficiencyActive, not recruiting

COVID-19Active, not recruiting

CIDPRecruiting

Corneal NeovascularizationPhase 1

Active, not recruiting

MyopathyPhase 2

Active, not recruiting

ImmunodeficiencyPhase 3

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

CIDPPhase 3

Recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

GAMUNEX-C

Grifols Therapeutics LLC

Phase 3

1 2

Spikevax

Moderna

Preclinical

21 3

Activella

Tricor

1 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 6

SARS-COV-2 VACCINE

Moderna

Preclinical

2 7

Achromycin V

WWyeth-Lederle Vaccines

Statin

1 9

Calcium

Eli Lilly

Preclinical

—10

Conventional

PPopulation Health Research Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

CIDP

NCT07540221

Clinical

Trials by Indication[1]

Immunodeficiency2 trials

Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency

Completed· Grifols Therapeutics LLC logo

Grifols Therapeutics LLC·Phase 4·NCT01465958·12 enrolled

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

Completed· Grifols Therapeutics LLC logo

Grifols Therapeutics LLC·Phase 3·NCT04561115·33 enrolled

COVID-191 trial

Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)

Completed· Grifols Therapeutics LLC logo

Grifols Therapeutics LLC·Phase 2·NCT04480424·100 enrolled

Corneal Neovascularization1 trial

Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions

Withdrawn·UUniversity of Utah·Phase 1·NCT02042027

Myopathy1 trial

Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

Withdrawn·UUniversity of Washington·Phase 2·NCT04450654

CIDP1 trial

An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Recruiting· Grifols Therapeutics LLC logo

Grifols Therapeutics LLC·Phase 3·NCT07540221·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for GAMUNEX-C. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GAMUNEX-C compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GAMUNEX-C. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Grifols Therapeutics LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Grifols Therapeutics LLC

GAMUNEX-C

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Immunodeficiency2 trials

COVID-191 trial

Corneal Neovascularization1 trial

Myopathy1 trial

CIDP1 trial

References

Drug Info

Quick Facts

Related News